CD2

Across TCGA pan-cancer cohorts, CD2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CD2 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CD2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CD2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and COAD are the cancer types where CD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.559	0.303	.007	17	view →
LUAD	DFS	Quartile	All	0.942	0.507	<.001	14	view →
COAD	DFS	Quartile	III,IV	0.797	1.000	.044	6	view →
CCRCC	DFS	Median	II,III,IV	0.724	0.489	.022	4	view →
LSCC	OS	Tertile	II,III,IV	0.624	0.889	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CD2–PDAC (OS)

Open the PDAC breakdown →